A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα）

Clinical trial NCT07690332 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07690332
Sponsor: NING LI-GYN
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL

Ovarian Cancer Fallopian Tube Cancers Primary Peritoneal Cancer

Start date: 2026-07-20
Primary completion: 2028-09-30
Enrollment: 400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.